subscribe now
toefl tse books
pcat books
toefl tse cds
pcat cds

 

Reference Guide For Pharmacy Mangement and Pharmacoeconomics-Questions and Answers (FPGEE)

Answers



ANSWER 6
(b) General member satisfaction can be measured by qualitative and quantitative assessment of telephone inquiries on help lines. Help lines assist the plan member to resolve inquiries related to pharmacy benefits. Automatic call distributor (ACD) measures the help line performance for PBM. The following industry standards are verified or measured:

1. Calls received.
2. Calls answered.
3. Calls abandoned.
4. Abandoned rate.
5. Percent of calls answered within 30 seconds.
6. Average speed of answer.
7. Average talk time.

ANSWER 7
(d) Atomoxetine (Strattera) is the first and only non-stimulant medication approved by the US Food and Drug Administration (FDA) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults. It is a norepinephrine reuptake inhibitor, a class of ADHD treatment that works differently from the other ADHD medications available. All other choices are controlled substances that can be diverted or abused.

ANSWER 8
(a) Reactively. States use different approaches to analyzing the prescription information they receive. A few states routinely analyze prescription data collected by the PDMPs to identify individuals, physicians, or pharmacies that have unusual use, prescribing, or dispensing patterns that may suggest potential drug diversion, abuse, or doctor shopping. States refer to this as a proactive approach to identifying drug diversion. Trend analyses are shared with appropriate entities, such as law enforcement, practitioners, and regulatory and licensing boards.
In contrast, most state PDMPs generally use the prescription data to respond to requests for information. These requests may come from physicians or from law enforcement or state officials based on leads about potential instances of diversion. According to state program officials, most PDMPs operate in the latter fashion, which is called reactively, because of the increased amount of resources required to operate a proactive system.

ANSWER 9
(b) Medigap usually covers the Part A coinsurance and for the cost of 365 extra days of hospital care during a patient’s lifetime after Medicare coverage ends. It also covers the Part B coinsurance (generally 20% of the Medicare-approved payment amount) and foreign travel emergency. In addition to these, some plans may cover limited prescription drug benefits and offer preventive care.

Medigap policy does not cover:

1. Long-term care.
2. Vision or dental care.
3. Hearing aids.
4. Private-duty nursing.
5. Unlimited prescription drugs.

ANSWER 10

(a) Current DUR procedures in most healthcare plans focus on product-centered utilization trends. For example, at the time of analyzing a DUR study most of the attention is given to drug products in terms of dollar costs and total unit dispensing rate. This sometimes may result in unwarranted physician inquiries and intervention that are not clinically significant. For example, if a patient is taking a proton pump inhibitor for several months, the computer will mark the patient profile to be reviewed for DUR under the category of “exceeds appropriate duration of use.” The DUR performer in this type of study does not look in depth for the past patient history of severe erosive esophagitis or gastric surgery.

>>> Next

 


Home | Books & Cd roms | MPJE cd roms | Contact Us |Sample Questions | Faq
        NAPLEX Books | NAPLEX Cds | California NAPLEX Books | California NAPLEX cds | FPGEE Books | FPGEE CDS | PCAT Books | PCAT CDS | PTCE Books | PTCE CDs | TOEFL/TSE Books | TOEFL/TSE CDS

 


ORDER NOW

View FLASH Presentation


NAPLEX®, FPGEE® and MPJE® are federally registered trademarks owned by the National Association of Boards of Pharmacy (NABP®), this Reference Guide or this web site is in no way authorized or sponsored by the NABP®. This reference guide or this web site is in no way authorized by or sponsored by the Pharmacy Technician Certification Boards, inc. (PTCB®) and California State Board of Pharmacy.

RXEXAM® is a registered trademark of Pharmacy Exam of Krishna Publication, Inc. Any unauthorized use of this trade mark would be considered the violation of law.

© 2000 Pharmacy Exam. All Rights Reserved.
Maintained & Powered by Mission Media